{"prompt": "['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', 'will be reported promptly to the overseeing IRB or CDC in accordance with institutional', 'requirements.', '8.2 Sources of Material', 'Medical history and immunization history will be obtained from the medical record when', 'available and from patient report. Demographic information will be obtained from the medical', 'record and patient report. Subjects will record solicited adverse reactogenicity events and any', 'medical intervention sought on study days 1-7 following each vaccination visit on the symptom', 'diary. Diary information will either be reported electronically or on paper which will be given to', 'the study team during a study visit. Diary information reported electronically will be preferred but', 'paper reporting will be allowed. The research staff will assess oral temperature.', '8.3 Potential Risks and Benefits', 'mRNA COVID-19 vaccines', 'Two COVID-19 vaccine received Emergency Use Authorization (EUA) by the FDA in December', '2020. BNT162b2 received FDA approval for individuals 16 years of age and mRNA-1273', 'received authorization for those >18 years of age. The Pfizer/BioNTech mRNA COVID-19', 'vaccine received additional EUA for adolescents 12 to 15 years in May 2021. These vaccines', 'have been recommended at these ages by the ACIP. Participants will be provided with the', 'respective fact sheets for the mRNA COVID-19 vaccine they receive including the BNT162b2', 'Ittps://www.fda.gov/media/144414/download and the MRNA-1273', 'Ittps://www.fda.gov/media/144638/download', 'Side effects that have been reported with mRNA COVID-19 vaccines include both injections site', 'reactions as well as general side effects. Injection site reactions include: pain, tenderness and', 'swelling of the lymph nodes in the same arm of the injection, swelling (hardness), and redness', 'at the injection site. General side effects include: fatigue, headache, muscle pain, joint pain,', 'chills, nausea and vomiting, fever and feeling unwell. There is a remote chance that an mRNA', 'COVID-19 vaccine could cause a severe allergic reaction, usually occurring within a few', 'minutes to hours after getting a dose of vaccine. Signs of a severe allergic reaction can include:', 'difficulty breathing, facial and throat swelling, tachycardia, total body rash, dizziness and', 'weakness. There have been rare reports of cases of inflammation of the heart-called', 'myocarditis and pericarditis-happening after mRNA COVID-19 vaccination25-27', 'The', 'events', 'have mainly occurred in adolescents and young adults and more often after the second dose of', 'vaccine. Available data from short-term follow-up suggest that most individuals have had', 'resolution of symptoms, but information is not yet available about potential long-term', 'sequelae 25,26 These may not be all the possible side effects of the mRNA COVID-19 vaccines.', 'Serious and unexpected side effects may also occur. mRNA COVID-19 vaccines are still being', 'studied in clinical trials. Available data support the safety of dose 3 mRNA COVID-19 vaccine', 'in immunocompromised individuals13', 'SD-IIV4 and HD-4', 'SD-IIV4 and HD-IIV4 are FDA-licensed vaccines approved for use in persons 6 months of age', 'and those >65 years old, respectively. Both vaccines are standard clinical practice and', 'recommended by the CDC. Participants will be provided with the CDC Vaccine Information', 'Statement (VIS) for IIV4 (https://www.cdc.gov/vaccines/hcp/vis/vis-statements/flu.pdt', '51']['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', 'IIV4 risks include minor problems such as soreness, redness, swelling, or pain where the shot', 'was given, hoarseness, sore, red or itchy eyes, cough, fever, aches, headache, itching, fatigue,', 'all of which usually occur within 1-2 days of vaccination and are self-limiting. More serious', 'problems including a small increased risk of Guillain-Barr\u00e9 Syndrome estimated at 1 or 2', 'additional cases per million people vaccinated can occur. This is much lower than the risk of', 'severe complications from influenza infection, which can be prevented by IIV443 In addition,', 'any medication can cause a severe allergic reaction, or anaphylaxis, which is estimated at ~', '1', 'in one million doses of IIV4 administered44.', 'General Vaccine Risks', 'Some people get severe pain in the shoulder and have difficulty moving the arm where a shot', 'was given. This happens very rarely. Syncope (fainting) can occur in association with', 'administration of injectable vaccines. Sitting or lying down when space is available for about 15', 'minutes can help prevent fainting, and injuries caused by a fall, as recommended in the ACIP', 'General Recommendations on Immunization 8. Subjects should inform their doctor if they feel', 'dizzy or have vision changes or ringing in the ears.', 'As with any licensed or authorized vaccine, protection may not occur in 100% of vaccinated', 'persons for either COVID-19 or influenza vaccines.', 'Blood Drawing', 'Risks of blood drawing include pain, swelling, bleeding, or bruising at the site where the blood', 'sample is collected. Subjects may also experience dizziness or fainting. There is a small risk of', 'infection around the vein where the blood was collected. Each study subject will be asked to', 'have up to 4 blood samplings with the total volume not to exceed 60mL over an approximately 4', 'month period of time.', 'Delay of Influenza Protection', 'There is a potential risk of a short delay in influenza protection by delaying the receipt of', 'influenza vaccine 2 weeks.', 'Confidentiality', 'An additional risk of study participation is the potential for loss of confidentiality.', '8.4 Adequacy of Protection Against Risks', '8.4.1 Protections against Risk', 'To decrease the possibility of infection at the site of blood drawing, the area on the arm above', 'the vein where blood will be taken will be prepped with 70% isopropyl alcohol antiseptic prior to', 'venipuncture.', 'Subjects will be counseled on possible side effects following vaccination and followed closely in', 'the immediate post-vaccination period and during the following week for assessment of', 'moderate to severe local or systemic reactogenicity. In the immediate post-vaccination period,', 'all subjects will be monitored in a sitting or lying position for 30 minutes following vaccinations to', 'help prevent fainting, and injuries caused by a fall. Subjects with a prior history of severe allergic', 'reaction after a previous dose of any influenza vaccine or COVID-19 vaccine, or to a vaccine', 'component, including egg protein, will be excluded from study enrollment. Epinephrine and', '52']\n\n###\n\n", "completion": "END"}